- $5.95bn
- $10.77bn
- $5.10bn
Bausch + Lomb Q2 revenue beats expectations, raises guidance
Brief: Bausch + Lomb Will Release Second-Quarter 2025 Financial Results On July 30
Brief: Bausch + Lomb Says Proceeds Used To Repay Outstanding Borrowings
Brief: Bausch + Lomb prices upsized senior secured notes offering
Brief: Bausch And Lomb Announces Launch Of Senior Secured Notes Offering, Refinancing Of Credit Agreement
Brief: Bausch + Lomb Launches Blink Nourish Lubricating Eye Drops And Blink Boost Lubricating Eye Drops In The United States
Brief: Bausch & Lomb Corp - On May 19, Bausch Health Companies Entered Letter Agreements With Icahn, Paulson, Kavanagh Groups - SEC Filing
Brief: Bausch + Lomb Launches Zenlens Chroma Hoa In The United States
Bausch + Lomb hits all-time low on quarterly surprise loss
Bausch + Lomb falls on quarterly surprise loss
Brief: Bausch + Lomb Reports More Than 100 Million Units Of Contacts Lenses, Lens Care And Eye Care Materials Collected Through One By One And Biotrue® Eye Care Recycling Programs
Bausch Health falls after RBC Capital Markets lowers PT
US FDA declines to approve Aldeyra's eye disease drug (updated)
US FDA declines to approve Aldeyra's eye disease drug
Bausch + Lomb recalls some of its implantable eye lenses
Brief: Bausch + Lomb Recalls Envista Aspire™, Envy™, And Certain Monofocal Intraocular Lenses
Brief: Bausch + Lomb Will Release First-Quarter 2025 Financial Results On April 30
Brief: Character Biosciences Raises $93 Million Series B to Advance Precision Medicine for Progressive Eye Diseases
Contact lens maker Bausch + Lomb rules out take-private deal (updated)